Article
Distinct prostate cancer neuroendocrine subtypes predict prognosis and guide personalized prostate-specific membrane antigen-targeted therapy
2024-09-30
Abstract excerpt
<h4>Background and Objective</h4> Second-generation hormonal therapy inhibits castration-resistant prostate cancer (CRPC), but the tumor eventually recurs as neuroendocrine prostate cancer (NEPC) and turns lethal. Differentiating lineage plasticity that contributed to distinct NEPC subtypes aids in advancing treatments, particularly the recent FDA-approved 177 Lu-PSMA-617 radiopharmaceutical therapy. <h4>Method...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 1028d7f2-c4ac-5b24-8fed-42b84a6506a7
- DOI
- 10.1101/2024.09.28.615561
